Resultado de búsqueda
Ben O'Leary is a Clinician Scientist at the ICR and an Honorary Consultant in Clinical Oncology at The Royal Marsden hospital, working in the Molecular Oncology group. Group: Targeted Therapy. +44 20 3437 7415.
View the profiles of people named Ben OLeary. Join Facebook to connect with Ben OLeary and others you may know. Facebook gives people the power to share...
CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor-positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been described preclinically, with limited evidence from clinical samples.
Benjamin O'Leary is a patient who had a brain tumor that caused him to say whatever he was thinking. Benjamin had been diagnosed with with a brain tumor. The tumor was pressing on his frontal lobe, causing him to say everything he thought. He had to be told directly that he was being rude...
17 de jun. de 2020 · There are a number of established molecular markers associated with poor outcome in early ER+ breast cancer, most notably the risk classifiers based on gene expression assessed in tumor biopsies, which are now routinely used to augment clinical decision making ( 9 ).
2 de jun. de 2019 · Dr Ben O’Leary discusses a new blood test for women with advanced breast cancer which can predict how well patients will respond to a new drug right at the s...
1 de oct. de 2020 · Ben's current research is focused on understanding the evolution of resistance to cancer therapies in breast and head and neck cancers. Ben's undergraduate training included Aerospace Engineering at The University of Cambridge and then Medicine at King's College London.
